Zydus Launches Tishtha, World's First Nivolumab Biosimilar

Zydus Lifesciences has introduced the world’s first biosimilar of Nivolumab, Tishtha, in India, marking a significant step in improving access to advanced immunotherapy for cancer patients.

This revolutionary step will enhance Zydus experience in biologics and immuno-oncology besides addressing the financial and accessibility dilemma affecting several cancer patients.

Tishtha has two strengths of 100mcg and 40mcg with 28950 and 13950 respectively. It is priced at a quarter of the reference product, which presents a more cost effective alternative to patients who undergo long term cancer therapies. The two-dose dosage can also be used to reduce wastage aiming at streamlining the treatment regimen towards improved cost management.

Also Read: India's Innovative Therapies Set Global Standard at Low Cost

Dr. Sharvil P Patel, Managing Director of Zydus Lifesciences, highlighted the fact that the aim of the company is to provide timely and affordable access to cancer treatments. Zydus has a desire to invest in high-quality biosimilars and the initiation of Tishtha signifies its dedication to patient-centred care.

Consistency, affordability, and access are the factors that determine the availability of modern cancer treatments. As continuous therapy is very vital and plays a critical role in ensuring the continuity of patients, Tishtha is a major contributor to the oncology treatments in the country since it will guarantee long-term service. It is created and produced in India and assists oncologists and healthcare systems to be able to offer quality care.

The introduction of Tishtha by Zydus is a great step in the right direction, towards the provision of immuno-oncology therapies to cancer patients throughout India with improved success.